The randomized, double-blind, placebo-controlled study is intended to evaluate the effectiveness of the drug for treating suicidal ideation and major depression, Acadia said Sept. 14. Select Acadia hospitals will be included.
Patients who exhibit specific symptoms will be eligible for enrollment in the study, Acadia said.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
